Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
23andMe has raised $912.5 m in total funding across 8 funding rounds for a $48.5 m valuation.

23andMe Capital Raised

Source: Stanford Venture Capital Initiative

23andMe Valuation

Source: Sharespost

23andMe Funding Rounds Summary

Founding Date


23andMe total Funding

$912.5 m

23andMe latest funding size

$82.5 m

Time since last funding

10 months ago

23andMe investors

Sequoia Capital, New Enterprise Associates, Google, DST Global, Google Ventures, Fidelity Investments, Mohr Davidow Ventures, Altimeter Capital, Xfund, Genentech, Johnson & Johnson Development Corporation, MPM Capital, National Institutes of Health, Illumina, Casdin Capital, Stephens Investment Management, GV, Anne Wojcicki, Euclidean Capital, Fidelity Management, Sergey Brin, GlaxoSmithKline, Wallenberg Foundations, NewView Capital, Raj Luhar, WuXi Venture Fund

23andMe's latest funding round in December 2020 was reported to be $82.5 m. In total, 23andMe has raised $912.5 m. 23andMe's latest valuation is reported to be $48.5 m.

23andMe Funding Rounds

DateAmount RaisedPost-money ValuationInvestors
Series AMay 2007$9 m$48.5 mNew Enterprise Associates, Google, Mohr Davidow Ventures, Genentech, Stephens Investment Management
Series BDec 2009$27.8 m$150.5 mNew Enterprise Associates, Google, Sergey Brin
Series CNov 2010$31.2 m$184.5 mNew Enterprise Associates, Johnson & Johnson Development Corporation, MPM Capital, GV
GrantDec 2012$573 kNational Institutes of Health
Series DDec 2012$58.4 m$288.7 mNew Enterprise Associates, DST Global, MPM Capital, GV, Anne Wojcicki, Sergey Brin
GrantJul 2014$1.4 mNational Institutes of Health
Series EJun 2015$150 m$1.1 bNew Enterprise Associates, Google Ventures, Xfund, MPM Capital, Illumina, Casdin Capital, Fidelity Management, WuXi Venture Fund
GrantOct 2016$1.7 m$1.1 bNational Institutes of Health
Series FSept 2017$250 m$1.7 bSequoia Capital, Fidelity Investments, Altimeter Capital, Casdin Capital, Euclidean Capital, Wallenberg Foundations
Series F-1Aug 2018$300 m$2.5 bGlaxoSmithKline
SecondaryJan 2019Raj Luhar
Series FDec 2020$82.5 mSequoia Capital, NewView Capital

Source: Stanford Venture Capital Initiative, Sharespost

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Footer menu